Effect of oral administration of dantrolene sodium on serum creatine kinase activity after exercice in horses with recurrent exertional rhabdomyolysis

American Journal of Veterinary Research

Volumn 65, Issue 1, 2004, Pages 74-79

  McKenzie, Erica C ^a,b   Valberg, Stephanie J ^a   Godden, Sandra M ^a   Finno, Carrie J ^a   Murphy, Michael J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DANTROLENE; WATER;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; EXERCISE; FOOD DEPRIVATION; HORSE DISEASE; MUSCLE STIFFNESS; MUSCLE WEAKNESS; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; RECURRENT DISEASE; RHABDOMYOLYSIS; SPECTROFLUOROMETRY; SWEATING; TIME; TREADMILL EXERCISE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; CREATINE KINASE; CROSS-OVER STUDIES; DANTROLENE; EXERTION; FOOD DEPRIVATION; HORSE DISEASES; HORSES; MUSCLE RELAXANTS, CENTRAL; RHABDOMYOLYSIS;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 0346025570     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.74     Document Type: Article

References (39)

1. Britt BA. Review article-dantrolene. Can Anaesth Soc J 1984;31:61-75.
2. Ward A, Chaffman MO, Sorkin EM. Dantrolene - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia and the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986;32:130-168.
3. 2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem 1997;272:26965-26971.
4. 3H]Azidodantrolene: synthesis and use in identification of a putative skeletal muscle dantrolene binding site in sarcoplasmic reticulum. J Med Chem 1999;42:1872-1880.
5. 3H]azidodantrolene by photoaffinity labeling. Biochemistry 2000;40:531-542.
6. Amelink GJ, Van der Kallen CJH, Wokke JHJ, et al. Dantrolene sodium diminishes exercise-induced muscle damage in the rat. Eur J Pharmacol 1990;179:187-192.
7. Laurence S. Oral dantrolene prevents rise of myoglobin due to suxamethonium. Anaesthesia 1985;40:907-910.
8. Flacco L, Colozzi A, Ripari P, et al. Dantrolene sodium in traumatic muscle contracture: double-blind clinical and pharmacological trial. Clin Ther 1989;11:623-632.
9. Haverkort-poels PJE, Joosten EMG, Ruitenbeek W. Prevention of recurrent exertional rhabdomyolysis by dantrolene sodium. Muscle Nerve 1987;10:45-46.
10. Gronert GA. Dantrolene in malignant hyperthermia (MH-susceptible patients with exaggerated exercise stress. Anesthesiology 2000;93:905.
11. Waldron-Mease E, Klein LV, Rosenberg H, et al. Malignant hyperthermia in a halothane-anesthetized horse. J Am Vet Med Assoc 1981;179:896-898.
12. Klein L, Ailes N, Fackelman GE, et al. Postanesthetic equine myopathy suggestive of malignant hyperthermia. A case report. Vet Surg 1989;18:479-482.
13. Manley SV, Kelly AB, Hodgson D. Malignant hyperthermia-like reactions in three anesthetized horses. J Am Vet Med Assoc 1983;183:85-89.
14. Valverde A, Boyd CJ, Dyson DH, et al. Prophylactic use of dantrolene associated with prolonged postanesthetic recumbency in a horse. J Am Vet Med Assoc 1990;197:1051-1053.
15. Harris P. Equine rhabdomyolysis syndrome. In: Robinson NE, ed. Current therapy in equine medicine 4. Philadelphia: WB Saunders Co, 1997;115-121.
16. Hodgson DR. Myopathies in the athletic horses. Compend Contin Educ Pract Vet 1985;7:S551-S555.
17. Beech J. Chronic exertional rhabdomyolysis. Vet Clin North Am Equine Pract 1997;13:145-167.
18. Court MH, Engelking LR, Dodman NH, et al. Pharmacokinetics of dantrolene sodium in horses. J Vet Pharmacol Ther 1987;10:218-226.
19. Waldron-Mease E. Correlation of post-operative and exercise induced equine myopathy with the defect malignant hyperthermia, in Proceedings. 22nd Annu Meet Am Assoc Equine Pract 1976; 24:95-99.
20. MacLeay JM, Sorum SA, Valberg SJ, et al. Epidemiologic analysis of factors influencing exertional rhabdomyolysis in Thoroughbreds. Am J Vet Res 1999;60:1562-1566.
21. Lentz LR, Valberg SJ, Balog EM, et al. Abnormal regulation of muscle contraction in horses with recurrent exertional rhabdomyolysis. Am J Vet Res 1999;60:992-999.
22. Lentz LR, Valberg SJ, Herold LV, et al. Myoplasmic calcium regulation in myotubes from horses with recurrent exertional rhabdomyolysis. Am J Vet Res 2002;63:1724-1731.
23. Lopez JR, Linares N, Cordovez G, et al. Elevated myoplasmic calcium in exercise induced equine rhabdomyolysis. Eur J Physiol 1995;430:293-295.
24. 2+], in muscle from humans with malignant hyperthermia. Muscle Nerve 1987;10:77-79.
25. Todi F, Mendonca M, Fenwick JD, et al. Determination of urine and plasma levels of dantrolene and metabolites in the horse after oral administration, in Proceedings. 41st & 42nd Meet Assoc Official Racing Chemists 1988/1999;212-220.
26. MacLeay JM, Valberg SJ, Pagan JD, et al. Effect of ration and exercise on plasma creatine kinase activity and lactate concentration in Thoroughbred horses with recurrent exertional rhabdomyolysis. Am J Vet Res 2000;61:1390-1395.
27. McKenzie EC, Valberg SJ, Godden SM, et al. Effect of dietary starch, fat and bicarbonate content on exercise responses and serum creatine kinase activity in equine recurrent exertional rhabdomyolysis. J Vet Intern Med 2003;17:693-701
28. Inotsume N, Higashi A, Matsukane I, et al. Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients. Pediatr Pharmacol 1986;5:253-259.
29. Meyler WJ, Bakker H, Kok JJ, et al. The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration. J Neurol Neurosurg Psychiatry 1981;44:334-339.
30. Allen GC, Cattran CB, Peterson RG, et al. Plasma levels of dantrolene following oral administration in malignant hyperthermia-susceptible patients. Anesthesiology 1988;69:900-904.
31. Serfas KD, Bose D, Patel L, et al. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family. Anesthesiology 1996;84:322-329.
32. Ward TL, Valberg SJ, Gallant EM, et al. Calcium regulation by skeletal muscle membranes of horses with recurrent exertional rhabdomyolysis. Am J Vet Res 2000;61:242-247.
33. Thomsen I, Shepherd RM, Fraser R, et al. Dantrolene inhibits adrenal steroidogenesis by a mechanism independent of effects on stored calcium release. J Steroid Biochem Mol Biol 1991;38:703-707.
34. Janjic D, Wollheim. CB, Sharp GW. Selective inhibition of glucose-stimulated insulin release by dantrolene. Am J Physiol 1982; 243:59-67.
35. Sumikawa K, Hayashi Y, Fukumitsu K, et al. Selective inhibition by dantrolene of caffeine induced catecholamine release from perfused dog adrenals. Res Commun Chem Pathol Pharmacol 1987;57:45-53.
36. Harrison GG. Dantrolene-dynamics and kinetics. Br J Anaesth 1988;60:279-286.
37. Chan CH. Dantrolene sodium and hepatic injury. Neurology 1990;40:1427-1432.
38. Roy S, Francis KT, Born CK, et al. Interaction of dantrolene with the hepatic mixed function oxidase system. Res Commun Chem Pathol Pharmacol 1980;27:507-520.
39. Francis KT, Hamrick ME. Dantrolene inhibition of the hepatic mixed function oxidase system. Res Commun Chem Pathol Pharmacol 1979;23:69-80.